FluoGuide is trading 5.08% lower at SEK 29.90, with no clear company-specific catalyst identified. - The latest company update, dated October 23, announced a Q3 webcast scheduled for November 26. Earlier clinical-trial and collaboration news were not reported as causes. - The broader-market snapshot was modestly positive and does not explain the decline; no volume or activity data was provided.